Levita Magnetics today announced the international launch of its MARS (magnetic-assisted robotic surgery) system with its placement at Hospital Luis Tisne in Santiago, Chile. Dr. Julio Jimenez used the system to perform same-day-discharge cholecystectomies (gallbladder removal) and bariatric surgeries. Jiminez previously helped Levita Magnetics with its clinical trials, said Levita Magnetics founder, CEO and President […]
Bariatrics
Intuitive leaders weigh in on GLP-1 drugs and surgical robotics procedures
Intuitive Surgical executives say they see benefits to their business from GLP-1 weight loss drugs, even if investors aren’t quite so sure. Intuitive’s stock slid in after-hours trading today after the company posted Q3 results that exceeded analysts’ expectations on profits but fell short on sales. Even if they had beat The Street on both […]
Apollo Endosurgery prices $21m offering
Apollo Endosurgery today priced a stock offering worth nearly $21 million for its line of bariatric and gastrointestinal devices. Austin, Texas-based Apollo said it plans to float roughly 3.75 million shares at $5.50 apiece, for gross proceeds of $20.6 million. The offering also includes a 45-day option for underwriter Craig-Hallum Capital of another 562,055 shares, […]
EnteroMedics jumps pre-market on BarioSurg buyout
EnteroMedics (NSDQ:ETRM) said today that it acquired BarioSurg and the gastric vest it developed to treat obesity, sending share prices surging in pre-market trading. The BarioSurg device is designed to be implanted via laparoscopy to wrap the stomach and emulate the effects of conventional bariatric surgery by temporarily reducing the stomach’s volume. St. Paul, Minn.-based […]
Study: GI Dynamics’ Endobarrier comparable to gastric bypass
Weight loss: 1st commercial implant of EnteroMedics’ Maestro device
GI Dynamics exercises 1-for-10 reverse split
GI Dynamics (ASX:GID) said it conducted a 1-for-10 reverse stock split in an effort to boost its flagging share price.
Weight loss: Gelesis, $22m in hand, registers $60m IPO
Gelesis just last week drummed up a $22 million funding round, but that’s not stopping the Boston-based company from registering for an initial public offering worth $60 million.
Obalon launches pivotal trial for weight-loss balloon
California’s Obalon Therapeutics said it launched a pivotal trial set for as many as 15 sites across the U.S. that will test its ingestible, gas-filled weight-loss balloon.
Apollo Endosurgery secures $50m loan
Apollo Endosurgery said it secured a $50 million term loan from Athyrium Capital Management it plans to use to refinance its debt.
GI Dynamics plunges 50% after FDA halts trial
